Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) brought to public attention that they have inaugurated a part one clinical study of Actimab-M in multiple Myeloma.
Actinium Pharmaceuticals is a pharmaceutical company that has curved its niche in innovating ingenious remedies for typical cancers that are insufficient in treatment options.
The company has taken to initiating the study against myeloma, in which measures can be taken to minimize growth of the tumor and cells. However, there is no cure for Multiple Myeloma. Most patients’ conditions deteriorate as they are exposed to more treatment.
Actimab-M is constructed by myeloid type, CD-33 targeting monoclonal antibody HuM-195 in fusion with the alpha-particle emitter actinium 225. The antigen CD33 is detailed to be existing on the malignant cells of the disease. It has been widely published that CD33 discovered on the malignant cells of multiple Myeloma is 25% – 35% of all patients. This identifies CD33 as one of the main prospects to be earmarked for treatment.
In this uncertain phase, Actimab-M will be employed on patients who exhibit advancing disease symptoms who had undergone 3 previous multiple Myeloma treatment schedules without much success. It will also be used on those whose conditions are frustratingly obdurate to QUAD (Caflizomib, Lenalidomide, Pomalidomide, Dexamethason).
Dr. M. Yair Levy of Texas Oncology – Baylor Charles A. Sammons Cancer Center stated this in view of the recently launched phase study, “relapsed and refractory multiple myeloma is an area of high unmet medical need that we hope to address with Actimab-M. Myeloma is a very radiosensitive cancer…”
Dr. Levy added that he believed through his research that he had done concerning Actimab-M, that the disease should abide better with this treatment. That the treatment could affirm their lab theories and become a milestone success, serving as an addition to the alternatives to manage the disease.
Sandesh Seth, chairman executive for Actinium Pharmaceuticals, shared a similar belief and moreover believed that this initiative launches the start of the enlargement of their scope beyond Acute myeloid leukemia (AML). It additionally highlights their extensive radioimmunotherapy technologies and their dedication in finding treatment for those in dire need.